Is Novavax (NASDAQ:NVAX) A Better Coronavirus Stock To Buy Now?
11:40 pm Saturday, August 21st, 2021
When it comes to certain stocks it might be a good idea for investors to be a bit more patient than usual in order to see the rewards and one of the stocks which could be in that category is that of Novavax (NASDAQ:NVAX).
In recent times, the stock has been in the middle of a rollicking rally and has made a remarkable recovery since slumping by 19% after announcing its financial results for the second fiscal quarter. It seems that the stock is on the move owing to the emergence of the Delta variant of the COVID 19 virus. The Delta variant has brought the issue of vaccines to the forefront once again and hence, it is no surprise that investors are again feeling bullish about Novavax.
The company has been working on its own product related to its vaccine and it is also working on getting approval from the United States Food and Drug Administration. However, Novavax has decided to move the timeline for its second application. It seems that the company has done so in order to build a sample size that could be considered large enough for the United States.
The company has also signed contracts with as many as 10 nations and unlike the vaccines from Moderna or Pfizer, there are no logistical challenges with the Novavax vaccine. However, FDA approval is going to be necessary if the company wants to taste success and that remains the key. Hence, at this point, investors need to be a bit patient with the Novavax stock.
